



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax: 022-2407 3462 / 2407 0144
Email: audit@aartidrugs.com
website: www.aartidrugs.com
CIN No.: L37060MH1984PLC055433

Ref: ADL/SE/2017-18

Date: 13th February, 2018

To,

Department of Corporate Services
BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai - 400 001

BSE CODE - 524348

BSE ID - AARTIDRUGS

National Stock Exchange of India
Limited

"Exchange Plaza",

Bandra - Kurla Complex,

Bandra(E), Mumbai - 400 051

NSE CODE: AARTIDRUGS

Sub: Outcome of Board Meeting held today i.e. 13th February, 2018 pursuant to Regulation 33 and 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Dear Sir,

Pursuant to Regulation 33 and 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we inform you that the Board of Directors at its Meeting held today i.e. Tuesday, 13th February, 2018 had *inter-alia* considered and approved the Audited Financial Results (Standalone & Consolidated) for the Quarter and nine months ended 31st December, 2017. Accordingly, please find enclosed herewith Statement of Audited Financial Results (Standalone & Consolidated) for the Quarter and nine months ended 31st December, 2017 along with the report of the Statutory Auditors.

The meeting commenced at 12.00 and concluded at 14.50.

The above is for your kind information and records. You are requested to acknowledge the receipt.

Thanking you,

Yours faithfully,

For Aarti Drugs Limited

Vibhav S. Ranade

Company Secretary & Compliance Officer

ICSI M. No. A35284



Encl: A/A

AARTI DRUGS LIMITED

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DEC, 2017

(Rs. in lakhs except for share data)

Sr. No.	Particulars	Standalone						Consolidated					
		Quarter Ended		Period Ended		Year Ended	Quarter Ended		Period Ended		Year Ended		
		31st Dec 2017 (Audited)	30th Sep 2017 (Audited)	31st Dec 2016 (Audited)	31st Dec 2016 (Audited)	31st Mar 2017 (Audited)	31st Dec 2017 (Audited)	30th Sep 2017 (Audited)	31st Dec 2016 (Audited)	31st Dec 2017 (Audited)	31st Dec 2016 (Audited)	31st Mar 2017 (Audited)	
I	Revenue from operations	30,821	28,820	28,594	84,467	89,411	1,18,593	33,541	31,927	31,021	93,188	96,784	1,28,808
II	Other income	13	8	80	27	143	353	13	8	87	28	183	400
III	Total Income (I + II)	30,834	28,827	28,674	84,494	89,554	1,18,947	33,554	31,935	31,108	93,216	96,967	1,29,208
IV	Expenses :												
	(a) Cost of materials consumed	19,014	16,295	13,848	53,844	52,381	67,806	20,562	17,111	15,377	58,290	56,848	74,020
	(b) Purchase of stock-in-trade	660	443	266	1,927	1,138	1,830	943	972	817	3,052	2,761	4,068
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(336)	1,751	2,944	(3,974)	(373)	366	(256)	2,052	2,848	(3,737)	(752)	(43)
	(d) Excise duty/taxes on goods sold	-	-	2,248	1,920	7,500	9,721	-	-	2,055	1,894	7,157	9,291
	(e) Employee benefits expense	1,296	1,236	1,137	3,721	3,470	4,748	1,501	1,426	1,271	4,287	3,854	5,283
	(f) Finance costs	844	760	860	2,639	3,448	906	803	909	2,603	2,784	2,784	3,642
	(g) Depreciation and amortisation expense	940	949	949	2,815	2,799	3,669	997	1,006	994	2,984	2,930	3,846
	(h) Other expenses	5,108	4,690	4,188	14,227	12,250	16,581	5,399	5,111	4,429	15,216	12,860	17,500
	Total expenses (IV)	27,526	26,124	26,440	76,931	81,806	1,08,169	30,051	28,482	28,699	84,588	88,441	1,17,607
V	Profit before exceptional items and tax (III - IV)	3,308	2,703	2,234	7,563	7,748	10,778	3,503	3,453	2,409	8,628	8,526	11,601
VI	Exceptional items	-	-	-	-	-	-	-	-	-	-	-	-
VII	Profit before tax (V - VI)	3,308	2,703	2,234	7,563	7,748	10,778	3,503	3,453	2,409	8,628	8,526	11,601
VIII	Tax Expenses :												
	Provision for taxation - Current	830	700	663	1,900	2,153	2,753	877	865	678	2,139	2,298	2,913
	- MAT credit entitlement	-	-	-	-	(203)	(203)	-	4	-	-	-	-
	- Earlier year	-	-	(203)	-	(203)	(203)	-	-	(203)	-	(203)	(203)
	Provision for deferred taxation	275	200	140	600	420	680	293	225	149	658	445	711
	Total tax expenses (VIII)	1,105	900	600	2,500	2,370	3,230	1,170	1,093	624	2,797	2,540	3,421
IX	Profit/(Loss) for the period from continuing operations (VII - VIII)	2,203	1,803	1,634	5,063	5,378	7,548	2,333	2,360	1,785	5,831	5,986	8,180
X	Profit / (Loss) from discontinuing operations	-	-	-	-	-	-	-	-	-	-	-	-
XI	Tax expenses of discontinuing operations	-	-	-	-	-	-	-	-	-	-	-	-
XII	Profit / (Loss) from discontinuing operations (X - XI)	-	-	-	-	-	-	-	-	-	-	-	-
XIII	Profit / (Loss) for the period (IX - XII)	2,203	1,803	1,634	5,063	5,378	7,548	2,333	2,360	1,785	5,831	5,986	8,180
XIV	Other Comprehensive Income	-	44	44	13	(109)	13	44	44	13	13	(109)	(109)
XV	Total Comprehensive Income for the period (XIII+XIV)	2,203	1,803	1,678	5,063	5,391	7,439	2,333	2,360	1,828	5,831	5,999	8,071
XVI	Paid up equity share capital (face value of Rs. 10 each)	2,386	2,386	2,386	2,386	2,386	2,386	2,386	2,386	2,386	2,386	2,386	2,386
XVII	Earning per equity share (in Rs.) (not annualised)												
	(1) Basic	9.23	7.56	6.93	21.22	22.27	30.84	9.78	9.89	7.56	24.44	24.78	33.46
	(2) Diluted	9.23	7.56	6.93	21.22	22.27	30.84	9.78	9.89	7.56	24.44	24.78	33.46

Notes :

- The above results for the quarter and period ended 31st December, 2017 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 13th February, 2018.
- Results for the quarter and period year ended 31st December, 2017 are in compliance with the Indian Accounting Standards (Ind-AS) notified by the Ministry of Corporate Affairs. Consequently results for quarter and Period ended 31st December, 2016 and previous year ended 31st March 2017 have been restated to comply with Ind-AS to make them comparable.

Reconciliation of the net profit to those reported under previous Generally Accepted Accounting Principles(GAAP) are summarised as follow :

Particulars	Standalone			Consolidated		
	3 Months Ended	9 Months Ended	12 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
	31st Dec 2016 (Audited)	31st Dec 2016 (Audited)	31st Mar 2017 (Audited)	31st Dec 2016 (Audited)	31st Dec 2016 (Audited)	30th Mar 2017 (Audited)
Net Profit as per previous IGAAP	1,634	5,378	7,424	1,785	5,986	8,056
Other Comprehensive Income (Net of tax)	44	13	15	44	13	15
Total Comprehensive Income as per Ind-AS	1,678	5,391	7,439	1,828	5,999	8,071

- Post the applicability of GST with effect from 1st July 2017, Sales are disclosed net of GST. Accordingly, the Gross Sales figures for the quarter and Period ended 31st December 2017 are not comparable with the sales figures depicted in the results for the previous periods.
- Company is operating as a single segment company, engaged in pharmaceutical business.
- Figures for the previous Quarter have been regrouped or rearranged wherever necessary.
- The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.com and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors.

Place: Mumbai
Date: 13th February, 2018

For AARTI DRUGS LIMITED



HARSHIT M. SAVLA
JT. MANAGING DIRECTOR



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)
Fax. : 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No. : L37060MH1984PLC055433

**Auditor's Report on Quarterly Standalone Financial Results of AARTI DRUGS LIMITED
Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015**

To
The Board of Directors of AARTI DRUGS LIMITED

We have audited the quarterly standalone financial results of AARTI DRUGS LIMITED ('the Company') for the quarter ended December 31, 2017 and year to date results for the period April 01, 2017 to December 31, 2017, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34 "Interim Financial Reporting", prescribed, under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

The comparative audited standalone financial statements for the quarter and nine months ended 31st December 2016, year ended 31st March 2017 and figures upto to 30th June, 2017 included in the year to date financial statements from 1st April 2017 upto 31st December 2017; including the reconciliation of profit under IND AS of the corresponding quarter ended 31st December 2016 and the year to date from 1st April 2016 to 31st December 2016 with the profit reported under previous GAAP, included in this statement have been audited by predecessor auditor "M/s Gokhale & Sathe, Chartered Accountants" whose report dated 8th February 2017 and 23rd May 2017 respectively have



expressed unmodified opinion on those audited financial statements, as adjusted for the differences in the accounting principles adopted by the Company on transition to the Ind AS which have been audited by predecessor auditor "M/s Gokhale & Sathe, Chartered Accountants" and has been relied upon by us for the purpose of our audit of the Statement.

In our opinion and to the best of our information and according to the explanations given to us these quarterly standalone financial results as well as the year to date results:

- (i) have been presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
- (ii) give a true and fair view of the net profit, total comprehensive income and other financial information for the quarter ended December 31, 2017 as well as the year to date results for the period from April 01, 2017 to December 31, 2017.

For GBCA & Associates

Chartered Accountants

Firm Registration No: - 103142W


Yogesh Amal
Partner
M. No. 111636



Place: Mumbai

Date: 13th February, 2018

**Auditor's Report on Quarterly Consolidated Financial Results of AARTI DRUGS LIMITED
Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015**

To
The Board of Directors of AARTI DRUGS LIMITED.

We have audited the quarterly consolidated financial results of AARTI DRUGS LIMITED ("the Company") for the quarter ended December 31, 2017 and the year to date consolidated financial results for the period from April 1, 2017 to December 31, 2017, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

These quarterly consolidated financial results have been prepared from consolidated interim financial statements, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial results based on our audit of such consolidated interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid Indian Accounting Standard (IND AS) 34 "Interim Financial Reporting", prescribed, under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

We did not audit financial statements/financial information of only subsidiary whose financial statement/financial information reflect total assets of Rs.9,519.92 Lakhs as at 31st December 2017, total revenues of Rs.3,380.12 lakhs and Rs.10,933.14 lakhs for the quarter ended and for nine months ended 31st December 2017 respectively as considered in the consolidated financial statements. These financial statements/ financial information have been audited by other auditor whose report have been furnished to us and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of its subsidiary is based solely on the report of the other auditor.



The comparative audited Consolidated financial statements for the quarter and nine months ended 31st December 2016 and year ended 31st March 2017 and figures upto to 30th June, 2017 included in the year to date financial statements from 1st April 2017 upto 31st December 2017; including the reconciliation of profit under IND AS of the corresponding quarter ended 31st December 2016 and the year to date from 1st April 2016 to 31st December 2016 with the profit reported under previous GAAP, included in this statement have been audited by predecessor auditor "M/s Gokhale & Sathe, Chartered Accountants" whose report dated 08th February, 2017 and 23rd May 2017 respectively have expressed unmodified opinion on those audited financial statements, as adjusted for the differences in the accounting principles adopted by the Company on transition to the Ind AS which have been audited by predecessor auditor "M/s Gokhale & Sathe, Chartered Accountants" and has been relied upon by us for the purpose of our audit of the Statement.

In our opinion and to the best of our information and according to the explanations given to us these quarterly and year to date consolidated financial results:

- (i) include the quarterly and year to date financial results of its only subsidiary, Pinnacle Life Science Private Limited
- (ii) have been presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
- (iii) give a true and fair view of the consolidated net profit and other financial information for the quarter ended December 31, 2017 as well as the year to date results for the period from April 1, 2017 to December 31, 2017.

For **GBCA & Associates**
Chartered Accountants
Firm Registration No: - 103142W


Yogesh Amal
Partner

M. No. 111636



Place: Mumbai
Date: 13th February, 2018